Canaccord lowered the firm’s price target on TransMedics (TMDX) to $109 from $169 and keeps a Buy rating on the shares. The firm noted its results missed expectations as the revenue shortfall was pinned on underlying volume in the US transplant market being more seasonally soft than expected, with the company’s quarter-over-quarter volume declines reflecting those of the entire market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: